Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...
Invitae Corporation faces significant challenges in addressing its liquidity concerns. Invitae has entered into an Asset Purchase Agreement with Natera, involving the sale of specific assets in the ...
Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...
SAN FRANCISCO, Dec. 13, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced strategic changes to streamline operations and reduce operating cash burn. The ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae cut about 1,000 jobs ...
– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results